Molecular profiles of high-grade and low-grade pseudomyxoma peritonei

Cancer Medicine

Volumn 4, Issue 12, 2015, Pages 1809-1816

  Noguchi, Rei ^a   Yano, Hideaki ^b   Gohda, Yoshimasa ^b   Suda, Ryuichiro ^b   Igari, Toru ^b   Ohta, Yasunori ^a   Yamashita, Naohide ^a   Yamaguchi, Kiyoshi ^a   Terakado, Yumi ^a   Ikenoue, Tsuneo ^a   Furukawa, Yoichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

DPAM; mutation; PMCA; pseudomyxoma peritonei; TP53

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

ADULT; AGED; AKT1 GENE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE; GENE IDENTIFICATION; GNAS GENE; HUMAN; HUMAN TISSUE; MALE; MIDDLE AGED; ONCOGENE K RAS; PATHOGENESIS; PERITONEUM PSEUDOMYXOMA; PHENOTYPE; PIK3CA GENE; PRIORITY JOURNAL; SOMATIC MUTATION; TUMOR SUPPRESSOR GENE; VERY ELDERLY;

EID: 84991529126     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.542     Document Type: Article

References (19)

1. Prayson, R. A., W. R. Hart, and R. E. Petras. 1994. Pseudomyxoma peritonei. A clinicopathologic study of 19 cases with emphasis on site of origin and nature of associated ovarian tumors. Am. J. Surg. Pathol. 18:591–603.
2. Smeenk, R. M., M. L. van Velthuysen, V. J. Verwaal, and F. A. Zoetmulder. 2008. Appendiceal neoplasms and pseudomyxoma peritonei: a population based study. Eur. J. Surg. Oncol. 34:196–201.
3. Misdraji, J., R. K. Yantiss, F. M. Graeme-Cook, U. J. Balis, and R. H. Young. 2003. Appendiceal mucinous neoplasms: a clinicopathologic analysis of 107 cases. Am. J. Surg. Pathol. 27:1089–1103.
4. Bradley, R. F., J. Ht. Stewart, G. B. Russell, E. A. Levine, and K. R. Geisinger. 2006. Pseudomyxoma peritonei of appendiceal origin: a clinicopathologic analysis of 101 patients uniformly treated at a single institution, with literature review. Am. J. Surg. Pathol. 30:551–559.
5. Jacquet, P., and P. H. Sugarbaker. 1996. Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J. Exp. Clin. Canc. Res. 15:49–58.
6. Vartiainen, J., H. Lassus, P. Lehtovirta, P. Finne, H. Alfthan, R. Butzow, et al. 2008. Combination of serum hCG beta and p53 tissue expression defines distinct subgroups of serous ovarian carcinoma. Int. J. Cancer 122:2125–2129.
7. Nummela, P., L. Saarinen, A. Thiel, P. Jarvinen, R. Lehtonen, A. Lepisto, et al. 2015. Genomic profile of pseudomyxoma peritonei analyzed using next-generation sequencing and immunohistochemistry. Int. J. Cancer 136:E282–E289.
8. Shetty, S., P. Thomas, B. Ramanan, P. Sharma, V. Govindarajan, and B. Loggie. 2013. Kras mutations and p53 overexpression in pseudomyxoma peritonei: association with phenotype and prognosis. J. Surg. Res. 180:97–103.
9. Nishikawa, G., S. Sekine, R. Ogawa, A. Matsubara, T. Mori, H. Taniguchi, et al. 2013. Frequent GNAS mutations in low-grade appendiceal mucinous neoplasms. Br. J. Cancer 108:951–958.
10. Sio, T. T., A. S. Mansfield, T. E. Grotz, R. P. Graham, J. R. Molina, F. G. Que, et al. 2014. Concurrent MCL1 and JUN amplification in pseudomyxoma peritonei: a comprehensive genetic profiling and survival analysis. J. Hum. Genet. 59:124–128.
11. Liu, X., K. Mody, F. B. de Abreu, J. M. Pipas, J. D. Peterson, T. L. Gallagher, et al. 2014. Molecular profiling of appendiceal epithelial tumors using massively parallel sequencing to identify somatic mutations. Clin. Chem. 60:1004–1011.
12. Furukawa, T., Y. Kuboki, E. Tanji, S. Yoshida, T. Hatori, M. Yamamoto, et al. 2011. Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas. Sci. Rep. 1:161.
13. Samuels, Y., Z. Wang, A. Bardelli, N. Silliman, J. Ptak, S. Szabo, et al. 2004. High frequency of mutations of the PIK3CA gene in human cancers. Science 304:554.
14. Velho, S., C. Oliveira, A. Ferreira, A. C. Ferreira, G. Suriano, S. Schwartz Jr, et al. 2005. The prevalence of PIK3CA mutations in gastric and colon cancer. Eur. J. Cancer 41:1649–1654.
15. Corless, C. L. 2014. Gastrointestinal stromal tumors: what do we know now? Mod. Pathol. 27(Suppl 1):S1–S16.
16. Corless, C. L., A. Schroeder, D. Griffith, A. Town, L. McGreevey, P. Harrell, et al. 2005. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J. Clin. Oncol. 23:5357–5364.
17. Hirota, S., A. Ohashi, T. Nishida, K. Isozaki, K. Kinoshita, Y. Shinomura, et al. 2003. Gain-of-function mutations of platelet-derived growth factor receptor α gene in gastrointestinal stromal tumors. Gastroenterology 125:660–667.
18. Shetty, S., B. Natarajan, P. Thomas, V. Govindarajan, P. Sharma, and B. Loggie. 2013. Proposed classification of pseudomyxoma peritonei: influence of signet ring cells on survival. Am. Surg. 79:1171–1176.
19. Davison, J. M., H. A. Choudry, J. F. Pingpank, S. A. Ahrendt, M. P. Holtzman, A. H. Zureikat, et al. 2014. Clinicopathologic and molecular analysis of disseminated appendiceal mucinous neoplasms: identification of factors predicting survival and proposed criteria for a three-tiered assessment of tumor grade. Mod. Pathol. 27:1521–1539.